Klaus Veitinger is the founder of Promentis Pharmaceuticals. Promentis Pharmaceuticals has raised $31M in total funding. Latest round: Series C.
Klaus Veitinger is the CEO and Chairman of the Board at Promentis Pharmaceuticals, as well as an OrbiMed Venture Partner. He leads the team focused on developing first-in-class therapies for neuropsychiatric disorders, including their lead compound SXC-2023.
Full founder directory · Investor directory · Company funding database · Fundraising library